Dementia and Alzheimer’s Statistics (2026)

Last Updated: June 2026

Dementia is not a single disease. It is an umbrella term for a group of symptoms caused by disorders that affect the brain — impairments in memory, communication, reasoning, and the ability to perform everyday tasks. Alzheimer’s disease is the most common cause, accounting for the majority of all diagnosed cases worldwide. Together, they represent one of the most significant medical, social, and economic challenges facing aging populations across every region of the globe.

The statistics in this article are drawn from primary sources including the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), the National Institute on Aging (NIA), the Alzheimer’s Association, and peer-reviewed journals including JAMA, The Lancet, and Neurology. They cover global and U.S. prevalence, economic costs, risk factors, racial and gender disparities, caregiver burden, and the current state of research and drug development.

For an overview of how dementia statistics fit within the broader landscape of brain health data, see our flagship article Brain Health Statistics: 50+ Key Facts (2026).

Key Dementia and Alzheimer’s Statistics at a Glance

• Approximately 55 million people worldwide are currently living with dementia. (WHO, 2023)
• Alzheimer’s disease accounts for 60 to 70% of all dementia cases globally. (WHO)
• Over 6.7 million Americans aged 65 and older are living with Alzheimer’s disease. (Alzheimer’s Association, 2023)
• The global cost of dementia care exceeded $1.3 trillion in 2023 and is projected to reach $2.8 trillion by 2030. (WHO)
• A new dementia case is diagnosed somewhere in the world every three seconds. (Alzheimer’s Disease International)
• By age 85, approximately one in three people will develop some form of dementia. (Alzheimer’s Association)
• Women account for nearly two-thirds of all Alzheimer’s cases in the United States. (Alzheimer’s Association)

Global Dementia Prevalence

The scale of dementia as a global health condition is difficult to overstate. Its reach extends across every income level, every region, and every demographic — though its burden is not evenly distributed.

Current Global Numbers

The most recent global data presents a picture of a condition already at crisis scale, with a trajectory that will demand substantial increases in health system capacity over the coming decades.

• Approximately 55 million people worldwide are currently living with dementia. (WHO, 2023)
  To put that figure in context, it is roughly equivalent to the entire population of South Korea living with a progressive neurological condition.
• More than 60% of people with dementia live in low- and middle-income countries, where healthcare infrastructure and diagnostic capacity are often least equipped to support them. (WHO)
  This geographic distribution means that the global burden of dementia falls most heavily on the regions least able to bear it.
• A new case of dementia is diagnosed every three seconds somewhere in the world. (Alzheimer’s Disease International)
  That rate translates to approximately 10 million new diagnoses per year globally — a number that reflects both rising incidence and improving detection.
• The number of people living with dementia is projected to reach 78 million by 2030 and 153 million by 2050. (WHO)
  The primary driver is demographic aging, not a worsening of disease biology — but the practical consequence is the same: a tripling of cases within a generation.

Prevalence by Region

Dementia rates vary considerably by geography, reflecting differences in population age structure, diagnostic access, and underlying risk factor prevalence.

• Europe and North America have the highest age-standardized dementia prevalence rates, driven by older average population ages. (IHME)
  However, absolute case numbers are growing fastest in East Asia, South Asia, and sub-Saharan Africa due to rapid population aging in those regions.
• Japan has one of the highest dementia prevalence rates among developed nations, with an estimated 6 to 7% of its total population affected. (Japanese Ministry of Health, Labour and Welfare)
  Japan’s experience is instructive for other rapidly aging societies, as it has been managing dementia at scale longer than most countries.
• In the United Kingdom, approximately 944,000 people are currently living with dementia, a number expected to exceed one million by 2025. (Alzheimer’s Research UK)
  The UK dementia care system is under significant structural pressure, with demand for specialist care growing faster than the trained workforce available to provide it.

Alzheimer’s Disease Statistics in the United States

The United States carries one of the largest absolute burdens of Alzheimer’s disease globally, driven by a large and aging population. National data from the Alzheimer’s Association provides some of the most detailed country-level statistics available.

Prevalence and Incidence

U.S.-specific prevalence data allows for more granular analysis by age, sex, race, and geography than global estimates typically permit.

• Over 6.7 million Americans aged 65 and older are living with Alzheimer’s disease as of 2023. (Alzheimer’s Association)
  Without a significant medical intervention, that number is projected to reach 13 million by 2050 as the baby boomer generation continues to age into higher-risk brackets.
• Approximately 200,000 Americans under the age of 65 have early-onset Alzheimer’s disease. (Alzheimer’s Association)
  Early-onset cases present particular challenges, as individuals are often still employed, financially active, and raising children when symptoms begin.
• One in nine Americans aged 65 and older has Alzheimer’s disease. (Alzheimer’s Association, 2023)
  The prevalence rises sharply with age: roughly one in three people aged 85 and older has the condition.
• Alzheimer’s disease is the seventh leading cause of death in the United States. (CDC)
  It is also one of the only top-ten causes of death with no disease-modifying treatment capable of stopping or reversing its progression.
• An estimated 6.1 million Americans have undiagnosed Alzheimer’s disease, meaning they are living with the condition without formal clinical identification. (Alzheimer’s Association)
  Underdiagnosis is a persistent barrier to early intervention, caregiver preparation, and access to clinical trials.

Age-Related Risk

Age is the single greatest risk factor for Alzheimer’s disease. The statistics on age-stratified prevalence illustrate how dramatically risk compounds after 65.

• The percentage of people with Alzheimer’s nearly doubles with every five-year increment of age beyond 65. (National Institute on Aging)
  This compounding pattern means that a relatively modest increase in average lifespan translates to a disproportionate increase in total Alzheimer’s cases.
• By age 85, approximately one in three people will develop some form of dementia. (Alzheimer’s Association)
  For individuals with a first-degree relative who had Alzheimer’s disease, the lifetime risk is estimated to be two to three times higher than for those without a family history.

Gender and Racial Disparities in Dementia

Dementia does not affect all population groups equally. Significant and well-documented disparities exist along gender and racial lines, driven by a combination of biological, socioeconomic, and structural factors.

Gender Disparities

Women bear a disproportionate share of the Alzheimer’s burden — both as patients and as caregivers.

• Women account for nearly two-thirds of all Americans with Alzheimer’s disease. (Alzheimer’s Association)
  Longevity accounts for part of this disparity, but researchers are also investigating hormonal factors, particularly the role of estrogen decline at menopause in accelerating amyloid accumulation.
• Women in their 60s are approximately twice as likely to develop Alzheimer’s disease over the rest of their lives as they are to develop breast cancer. (Alzheimer’s Association)
  Despite this, Alzheimer’s receives significantly less public health awareness and research funding relative to its prevalence and lethality compared to breast cancer.
• Women provide an estimated 63% of all hours of unpaid dementia caregiving in the United States. (Alzheimer’s Association)
  The caregiving burden falls disproportionately on women both as spouses and as adult daughters, compounding the economic and health costs the condition imposes on them.

Racial Disparities

Black and Hispanic Americans face significantly elevated dementia risk compared to white Americans — disparities rooted in structural inequities rather than biology alone.

• Black Americans are approximately twice as likely as white Americans to develop Alzheimer’s disease and other dementias. (Alzheimer’s Association)
  Higher rates of hypertension, diabetes, and cardiovascular disease — conditions strongly linked to vascular dementia risk — are primary contributors to this disparity.
• Hispanic Americans are approximately one and a half times more likely to develop dementia than non-Hispanic white Americans. (Alzheimer’s Association)
  Researchers point to socioeconomic barriers to education, healthcare access, and brain-healthy lifestyle factors as key drivers of this elevated risk.
• Black and Hispanic Americans are significantly underrepresented in Alzheimer’s clinical trials, comprising a small fraction of research participants despite their elevated disease burden. (NIH)
  This underrepresentation limits the generalizability of trial findings and slows development of interventions suited to the populations most affected.

Economic Cost of Dementia

The financial cost of dementia — measured in direct medical expenses, long-term care costs, and unpaid family labor — is one of the largest of any disease category. These figures capture only what can be quantified; the emotional and social costs extend far beyond any accounting.

• The total global cost of dementia exceeded $1.3 trillion in 2023. (WHO)
  That figure is projected to reach $2.8 trillion by 2030, a doubling driven by rising case counts, increasing care intensity, and the growing share of costs falling on formal care systems.
• In the United States, Alzheimer’s and other dementias cost an estimated $345 billion in 2023, including Medicare, Medicaid, and out-of-pocket expenses. (Alzheimer’s Association)
  By 2050, those costs are projected to exceed $1 trillion annually in the U.S. alone.
• The average lifetime cost of care for a person with Alzheimer’s disease in the United States is estimated at $350,000 to $400,000. (JAMA)
  A large portion of this cost is borne by families directly, either through out-of-pocket payments or unpaid caregiving that displaces paid work.
• In 2022, family caregivers of people with Alzheimer’s and dementia provided an estimated 18 billion hours of unpaid care. (Alzheimer’s Association)
  At the federal minimum wage, that labor would be valued at approximately $340 billion — a figure that does not appear in any national accounts.
• Nearly 60% of dementia caregivers report high or very high emotional stress related to their caregiving responsibilities. (Alzheimer’s Association)
  Caregiver burnout is associated with elevated rates of depression, physical illness, and premature mortality — making caregiver health a direct extension of the dementia public health problem.

Risk Factors for Dementia and Alzheimer’s Disease

Not all dementia risk is fixed at birth. Research has identified a significant number of modifiable risk factors — conditions and behaviors that increase the probability of developing dementia and that can be meaningfully addressed through lifestyle and medical intervention.

Modifiable Risk Factors

A landmark 2020 analysis published in The Lancet identified 12 potentially modifiable risk factors for dementia, accounting for approximately 40% of all cases worldwide.

• Hearing loss is the single largest modifiable risk factor for dementia, accounting for an estimated 8% of all cases. (The Lancet, 2020)
  The mechanism is believed to involve increased cognitive load compensating for hearing impairment, combined with reduced social engagement when communication becomes difficult.
• Physical inactivity accounts for approximately 2% of dementia cases globally and is associated with a 35% higher Alzheimer’s risk. (The Lancet)
  Exercise is one of the few lifestyle interventions with consistent, replicated evidence for both prevention and symptom delay.
• Smoking increases dementia risk by approximately 60% compared to non-smokers. (WHO)
  Vascular damage and oxidative stress are the primary mechanisms — and quitting smoking at any age appears to reduce the elevated risk over time.
• Depression is associated with a 65% higher risk of developing dementia over a lifetime. (JAMA Psychiatry)
  Whether depression is a causal risk factor or an early symptom of underlying neurodegeneration — or both — remains an active area of research.
• Low educational attainment is associated with a two- to three-fold increased risk of dementia. (NIA)
  Education is thought to build cognitive reserve — the brain’s capacity to sustain function despite pathological damage — rather than preventing the underlying biology of disease.
• Type 2 diabetes increases dementia risk by approximately 60 to 65%. (Diabetes Care)
  This connection has led some researchers to characterize Alzheimer’s disease as a form of insulin resistance in the brain, sometimes informally called “type 3 diabetes.”

Genetic Risk Factors

Genetics plays a meaningful but not deterministic role in most dementia cases. The picture is more complex than a simple inherited risk.

• The APOE e4 gene variant is the most significant known genetic risk factor for late-onset Alzheimer’s disease, increasing risk by three to four times in carriers of one copy and by eight to twelve times in carriers of two copies. (NIA)
  Approximately 25% of the U.S. population carries at least one copy of APOE e4, though carrying the variant does not guarantee developing the disease.
• Early-onset familial Alzheimer’s disease, caused by rare mutations in APP, PSEN1, or PSEN2 genes, accounts for less than 1% of all Alzheimer’s cases. (NIA)
  These mutations cause almost certain disease development, often before age 65, and are the basis for a number of high-profile family studies and clinical trials.

Dementia Research and Drug Development Statistics

Progress in Alzheimer’s treatment has been historically slow, marked by decades of clinical trial failures. Recent years have seen the first disease-modifying approvals, though their scope remains limited and their cost remains high.

• More than 99% of Alzheimer’s drug candidates have failed in clinical trials between 1998 and 2017. (Cleveland Clinic Journal of Medicine)
  The failure rate is among the highest of any disease category, reflecting the complexity of the blood-brain barrier, the heterogeneity of the disease, and the challenge of identifying the condition early enough for intervention.
• The FDA approved lecanemab (Leqembi) in 2023 as the first Alzheimer’s drug to demonstrate significant slowing of clinical decline in a Phase 3 trial. (FDA / NEJM)
  The drug reduced cognitive decline by approximately 27% over 18 months — a meaningful result, though not a cure, and accompanied by serious side effects in a subset of patients.
• The NIH invested approximately $3.9 billion in Alzheimer’s and related dementia research in fiscal year 2023. (NIH)
  That figure represents a tenfold increase from 2011 levels, reflecting both the scale of the crisis and sustained bipartisan congressional support for research funding.
• Blood-based biomarker tests for Alzheimer’s disease have demonstrated accuracy rates exceeding 90% in detecting amyloid pathology in recent clinical studies. (Nature Medicine)
  These tests represent a potential shift from expensive PET scans and invasive spinal fluid testing to scalable, accessible early detection — a development that could significantly change the diagnostic landscape.
• Approximately 110 drugs are currently in clinical trials for Alzheimer’s disease across Phase 1, 2, and 3 studies as of 2024. (Alzheimer’s Association Clinical Trials Finder)
  The pipeline has diversified beyond amyloid-targeting therapies to include tau-targeting drugs, neuroinflammation modulators, and neuroprotective agents.

Early-Onset Dementia and Younger Adults

While dementia is predominantly associated with older adults, a significant and often overlooked population develops the condition at younger ages — with distinctive challenges and a distinct pattern of impact.

• Approximately 3.9 million people worldwide are estimated to have early-onset dementia, defined as diagnosis before age 65. (Alzheimer’s Disease International)
  Early-onset cases are more likely to involve non-Alzheimer’s dementia subtypes, including frontotemporal dementia, which disproportionately affects individuals in their 40s and 50s.
• Frontotemporal dementia is the most common dementia in people under 60, affecting an estimated 50,000 to 60,000 Americans. (UCSF Memory and Aging Center)
  Unlike Alzheimer’s, frontotemporal dementia often presents first with personality changes and language difficulties rather than memory loss, leading to frequent misdiagnosis as a psychiatric condition.
• People with Down syndrome have a 50 to 70% lifetime risk of developing Alzheimer’s disease, typically at younger ages than the general population. (National Down Syndrome Society / NIA)
  The triplication of chromosome 21 — which carries the gene for amyloid precursor protein — drives an accelerated amyloid accumulation pattern in this population.
• Early-onset dementia is associated with significantly higher rates of depression and suicidal ideation than late-onset dementia, and a much shorter average time from diagnosis to severe disability. (Journal of Neurology, Neurosurgery and Psychiatry)
  The psychosocial disruption of receiving a dementia diagnosis while still employed, parenting, or financially active is qualitatively different from the experience of older patients.

The intersection of age and cognitive decline is explored more broadly in our article on Brain Health Statistics by Age.

Prevention and Protective Factors

The absence of a cure makes prevention and risk reduction the most actionable area of dementia science for most people. A growing body of evidence identifies specific behaviors and conditions that meaningfully reduce the probability of developing dementia.

• Cognitive reserve — built through education, social engagement, and mental challenge — can delay dementia symptom onset by up to 10 years despite underlying brain pathology. (Alzheimer’s Association)
  This delay has profound quality-of-life implications: a decade of preserved function represents an enormous difference in lived experience for patients and families.
• Regular aerobic exercise reduces Alzheimer’s risk by approximately 35%. (The Lancet)
  Exercise promotes blood flow, stimulates production of brain-derived neurotrophic factor (BDNF), and reduces several modifiable dementia risk factors simultaneously, including blood pressure, diabetes risk, and depression.
• The Mediterranean and MIND diets are each associated with a 30 to 35% reduction in dementia risk. (NEJM, MIND Trial)
  Both dietary patterns emphasize anti-inflammatory foods — olive oil, leafy greens, fatty fish, nuts, and berries — that support vascular and neuronal health.
• Social isolation is associated with a 50% increased risk of dementia. (NASEM Report on Social Isolation and Loneliness)
  The mechanism is thought to involve reduced cognitive stimulation, elevated stress hormones, and the downstream effects of depression and physical inactivity that often accompany isolation.
• Treating hypertension in midlife reduces dementia risk by approximately 15%. (The Lancet, 2020)
  Hypertension is one of the most prevalent and most treatable risk factors for vascular dementia, making blood pressure management a high-leverage preventive intervention.

For data on how exercise specifically affects brain structure and cognition, see our article on Exercise and Brain Health Statistics. For dietary data, see Nutrition and Brain Health Statistics.

Key Takeaways

• Dementia currently affects approximately 55 million people worldwide, with a new diagnosis occurring every three seconds — a scale that makes it one of the defining health challenges of the 21st century. (WHO, Alzheimer’s Disease International)
• Women bear a disproportionate burden as both patients and caregivers, accounting for nearly two-thirds of Alzheimer’s cases and providing an estimated 63% of all unpaid dementia care hours in the United States. (Alzheimer’s Association)
• Approximately 40% of dementia cases worldwide are attributable to modifiable risk factors — meaning a substantial proportion of future cases could be prevented or delayed through public health action. (The Lancet, 2020)
• The global cost of dementia care exceeded $1.3 trillion in 2023 and is on track to double by 2030, making it one of the most costly conditions in the history of human disease. (WHO)
• Cognitive reserve built through education, exercise, social engagement, and diet can delay dementia symptom onset by up to 10 years — the most practical and accessible preventive strategy currently available to most people. (Alzheimer’s Association)

Explore the Full Brain Health Statistics Series

• Brain Health Statistics: 50+ Key Facts (2026)
• Dementia and Alzheimer’s Statistics
• Sleep and Brain Health Statistics
• Nootropics Industry Statistics and Market Data
• Mental Health and Cognitive Function Statistics
• Brain Health Statistics by Age
• Exercise and Brain Health Statistics
• Screen Time and Brain Health Statistics
• Nutrition and Brain Health Statistics
• Stress and the Brain: Key Statistics
• Student Brain Health and Academic Performance Statistics
• Creativity and the Brain: Key Statistics
• Biohacking Statistics and Trends
• AI and Cognitive Impact Statistics
• Brain Injury and Concussion Statistics